SEC Filing Summary: Hemispherx Biopharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Hemispherx Biopharma, Inc. on July 8, 2005. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities. The company is a biopharmaceutical firm based in Philadelphia, Pennsylvania, focused on the production of Ampligen(R) and Alferon N injections.
Key Financial Metrics and Transaction Details
- Financing Agreement: Entered into a Common Stock Purchase Agreement with Fusion Capital Fund II, LLC.
- Total Commitment: Up to $20,000,000 in common stock purchases over approximately 25 months.
- Initial Issuance: 402,798 shares of common stock issued immediately upon signing.
- Pricing Mechanism: Future shares will be sold at the lower of the day's lowest trade price or the average of the three lowest closing prices from the preceding 12 trading days.
- Daily Cap: The Company may sell up to $40,000 of stock per trading day once the registration statement is effective.
- Use of Proceeds: Facility extension in New Brunswick for production and general corporate purposes.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes
The primary material change is the establishment of a new financing facility with Fusion Capital, providing a potential capital source of $20 million. This represents a significant shift in the company's capital structure and liquidity position compared to the prior period, though specific comparative financial data is not included in this 8-K.
Outlook, Risks, and Management Commentary
Management intends to utilize the proceeds to expand manufacturing capabilities for its key products, Ampligen(R) and Alferon N. The agreement includes a Registration Rights Agreement requiring the filing of a registration statement with the SEC. A potential risk or contingency involves the variable pricing mechanism, which ties the purchase price to the lowest recent market trading prices, potentially diluting existing shareholders if the stock price declines.
Key Facts for Investor Verification
- Verify the effectiveness date of the Registration Statement to determine when the daily $40,000 sales can commence.
- Review the full Common Stock Purchase Agreement (Exhibit 10.1) for specific conditions under which Fusion Capital may be required to purchase greater amounts of stock.
- Confirm the current market price of Hemispherx common stock to estimate the dilution impact of the initial 402,798 shares and future issuances.
- Check subsequent filings for updates on the utilization of the $20 million commitment and the status of the New Brunswick facility expansion.